Monthly research recap
Psilocybin research: March 2026
What March 2026's 25 new studies found, synthesized from the papers below. All Psilocybin research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, then ranked by relevance.
In March 2026, research on psilocybin showed mixed results: the largest and most rigorous trial (EPIsoDE) failed its primary endpoint for treatment-resistant depression, while smaller trials and observational studies suggested potential benefits for OCD and smoking cessation. Preclinical work consistently found psilocin enhances neuroplasticity in human neurons and dampens aversive representations in mice, but clinical evidence is limited by small samples, open-label designs, and blinding failures.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5'-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin. 2026 | computational/in silico | Unclear | In silico toxicity assessment classified psilocybin and related tryptamines as high toxicological concern with moderate-to-high acute toxicity and potential cardiotoxicity. | |
| Reshaping human neurons. 2026 | preclinical (in vitro) | Supports | Psilocin increased structural complexity and synaptic connections in human neurons derived from stem cells. | |
| Psychedelics in NHS services: exploring a model for real-world implementation of psilocybin 2026 | theoretical/model | Unclear | Discussed a model for implementing psilocybin therapy in publicly funded health services, emphasizing need for high-quality evidence and equitable access. | |
| Therapist Manual for Psilocybin-Assisted Therapy of Treatment-Resistant Major Depression 2026 | theoretical/manual | Unclear | Provided a therapist manual for psilocybin-assisted therapy in TRD, describing set and setting, therapist dyad model, and integration sessions. | |
| Associations Between Psilocybin Use Motives and Cognitive, Affective, and Behavioural Self-Stigma. 2026 | observational (cross-sectional) | 239 | Mixed | Therapeutic growth motives for psilocybin use were associated with reduced self-stigma, while social recreation motives were associated with increased self-stigma. |
| Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons. 2026 | preclinical (in vitro) | Supports | Psilocin increased BDNF, enhanced neuronal complexity and synaptic proteins, and increased excitability and network activity in human cortical neurons. | |
| Psilocybin Attenuates Cortical Representations of Aversion in the Mouse Auditory Cortex. 2026 | preclinical (animal) | Supports | Psilocybin selectively reduced responses to aversive stimuli and well-consolidated aversive-associated tones in mouse auditory cortex without affecting reward or new aversive learning. | |
| Psychedelic Experiences and Finitude in Serious Illness: A Qualitative Synthesis 2026 | qualitative systematic review | 9 | Supports | Qualitative synthesis identified a transformation in relationship with finitude, from threat to expanded states, in people with serious illness using psychedelics. |
| Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors 2026 | observational (fMRI) | Supports | Psilocybin modulated slow propagation of brain activity over the cortical layout of 5HT2a receptors, linking receptor distribution to global brain events. | |
| Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial 2026 | open-label extension of RCT | Unclear | Open-label extension of a phase II RCT for alcohol use disorder; abstract not provided, so direction cannot be determined. | |
| Psilocybin in Neuropsychiatric Disorders: Seeking Valuable Evidence in History, Pure Science, Clinical Trials and Real-World Data (RWD). 2026 | narrative review | Mixed | Review found rapid and sustained antidepressant/anxiolytic effects in highly cited trials but noted RCTs may not capture therapeutic complexity due to contextual factors. | |
| Psilocybin: Chemical Foundations and Emerging Therapeutic Potential. 2026 | review | Supports | Mini review summarized psilocybin's chemistry, pharmacology, and therapeutic potential in depression, noting challenges in large-scale synthesis. | |
| Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility 2026 | editorial | Unclear | Editorial highlighted methodological limitations (blinding, expectancy, ethical missteps) and called for improved trial designs to ensure credibility. | |
| Psilocybin, Lp(a), CAC, Niere und Darmkrebs – Evidenz-Quickies KW 12 2026 | news/commentary | Opposes | Commentary reported that the EPIsoDE trial failed its primary endpoint for TRD, with secondary signals confounded by broken blinding and expectancy effects. | |
| Psilocybin effects on brain functional connectivity: a systematic review of fMRI studies 2026 | systematic review | 20 | Mixed | Systematic review of fMRI studies found inconsistency in methods and designs, with high dropout rates and lack of follow-up scanning, though key regions (amygdala, ACC, PFC) were identified. |
| Raman Activity Investigation and Utilization of Psilocybin 2026 | methodological/analytical | Unclear | Developed a Raman spectroscopy-based method for rapid, nondestructive identification of psilocybin in mushrooms. | |
| Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression 2026 | RCT (phase 2b) | 144 | No effect | The EPIsoDE trial found that psilocybin 25 mg did not significantly reduce HAMD17 scores at week 6 compared to placebo, failing the primary endpoint. |
| Enlightenment in a Pill—Testing the Efficacy of Psilocybin 2026 | commentary | Unclear | Commentary questioned whether psilocybin-assisted therapy works via mystical experience rather than direct biological drug effect. | |
| Explainable AI framework for psilocybin depression treatment optimization 2026 | computational modeling | Unclear | Developed an XAI framework for optimizing single-dose psilocybin treatment protocols using simulated data, not real patient treatments. | |
| A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive–compulsive disorder 2026 | RCT | 15 | Supports | Psilocybin significantly reduced YBOCS scores in OCD patients, with 73.3% responders after eight high doses, and effects diminished but remained substantial at 6 months. |
| The renaissance of research on psychedelics in child and adolescent psychopharmacology 2026 | review | Unclear | Review noted that psychedelic research in adolescents is in early stages, with potential targets but requiring caution due to developmental vulnerabilities. | |
| Psilocybin Trends in States That Decriminalized Use 2026 | survey study | Unclear | Survey estimated an increase in 12-month psilocybin use associated with decriminalization in Oregon and Colorado. | |
| Psilocybin decreases preference for large rewards accompanied by increased activity of parvalbumin neurons with perineuronal nets in the medial prefrontal cortex. 2026 | preclinical (animal) | Mixed | Psilocybin decreased preference for large rewards and increased latency to large rewards, not consistent with impulsivity changes, and increased activity of PV interneurons with PNNs in mPFC. | |
| Study 24953 | survey study | 106 | Unclear | Survey of Oregon's first psilocybin facilitators found diverse workforce, high training costs, and mean planned session price of $1,388. |
| Psilocybin or Nicotine Patch for Smoking Cessation 2026 | RCT (pilot) | 82 | Supports | Psilocybin plus CBT produced higher biochemically verified prolonged smoking abstinence at 6 months compared to nicotine patch plus CBT. |
Points of agreement
- Preclinical studies consistently show psilocin/psilocybin enhances neuroplasticity in human neurons and reduces aversive representations in animal models.
- Multiple reviews and editorials agree that methodological limitations (blinding, expectancy, small samples) are major challenges in psilocybin research.
- Several studies point to the importance of contextual factors (set, setting, therapeutic support) in psilocybin's effects.
Conflicts
- The largest RCT (EPIsoDE) failed its primary endpoint for TRD, while smaller trials (OCD, smoking cessation) showed positive results, creating a conflict in clinical efficacy evidence.
- Commentary and editorial sources argue that positive findings may be inflated by broken blinding and expectancy effects, whereas other studies interpret positive signals as genuine.
- In silico toxicity predictions suggest moderate-to-high acute toxicity, while clinical trials report psilocybin as generally well-tolerated with no serious adverse events.
Gaps
- Durability of effects beyond 6 months is rarely assessed in clinical trials.
- Blinding integrity and expectancy effects are not systematically measured in most studies.
- Pediatric and adolescent populations remain largely unstudied.
- Standardized dosing protocols and long-term safety data are lacking.
- Real-world implementation models and workforce training are in early stages with limited evidence.